The stock jumped 7.96 per cent and ended the day at Rs 99.70 on BSE. Intra-day the stock had surged 16.29 per cent.
On NSE, shares of the company went up by 7.72 per cent and settled at Rs 99.80. During the day, the stock had risen 16.99 per cent to touch an intra-day high of Rs 108.40.
The company's 'Finished Dosage Form' manufacturing facility had a favourable outcome post its US Food and Drug Administration (USFDA) inspection. The audit was conducted during the last week of November and concluded on November 28, 2016.
"We believe that this satisfactory outcome will support our endeavour to further strengthen our positioning in the global markets," Vivimed Labs MD Santosh Varalwar had said.